BioSig Technologies : Corporate Summary

PURE EP™ System

NASDAQ: BSGM

BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals within the rapidly growing $4.6 billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of

Directors and Scientific Advisory Board, Los Angeles-based BioSig is preparing to commercialize its PURE EP™ System. PURE EP™ is a signal acquisition and processing system designed to assist electrophysiologists in making clinical decisions in real-time to help identify areas of tissue that create a heart rhythm disturbance (arrhythmia). PURE EP™ is designed to support catheter ablation cases, working in parallel with existing recording and mapping systems. BioSig's goal is to improve the standards of care in electrophysiology and increase the number of patients who can have their condition successfully treated during the first procedure.

Key Growth Drivers

1. Advanced Technology - The non-invasivePURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. The system is indicated for use under the supervision of licensed healthcare practitioners who are responsible for interpreting the data. The PURE EP System aims to minimize noise and artifacts, and acquire high-fidelity cardiac signals. Improving cardiac signals may potentially increase the diagnostic value of these signals, thereby possibly improving accuracy and efficiency of the EP studies and ablation procedures. The PURE EP™ System received FDA 510(k) clearance in August
   2018.
2. Market Opportunity - Market Research Engine states the global electrophysiology (EP) device market is expected to exceed more than US $8.5 billion by 2024 and is growing at a compound annual growth rate (CAGR) of 10.6%. The Company also operates within the rapidly emerging field of bioelectronic medicine, estimated at $3.75 billion in 2017 with projected annual growth of 14.2%.
3. KOL Support - First successful clinical use of PURE EP™ System was led by two globally recognized leaders: Dr. Andrea Natale of Texas Cardiac Arrhythmia Institute and Prof. John M. Miller of Indiana University. The Company achieved proof of concept validation through UCLA, and performed eighteen pre-clinicalstudies at Mayo Clinic, MN under the leadership of Samuel J. Asirvatham, M.D., Mayo Clinic's Vice-Chairof Innovation and Medical Director, Electrophysiology Laboratory.

Market Snapshot

NASDAQ: BSGM

Price (1/03/20)	$6.14
Average	75,681
Volume (50 day)
52-Wk. Range	$4.06 -
$9.97
Float	16.24M
Shares	22.17M
Outstanding
Market Cap	$136.13M

Recent Highlights

• Announced partnership with Reified on development of artificial intelligence (AI) solutions in healthcare
• Commenced its first clinical trial for its PURE EP™ System
• Opened a technology development office in Rochester, Minnesota
• Signed a new licensing agreement with Mayo Clinic in Sept. '19 - 3 new agreements signed in Nov '19
• BioSig's subsidiary NeuroClear Technologies, Inc. raised $3.7 million in an initial seed round
• Allowed additional foundational US Patent for its PURE EP™ System
• Appointed five new senior industry hires: Andrew Ballou - Vice President of Investor Relations; Julie Stephenson, BSN, MBA - Senior Director of Clinical Affairs; Olivier Chaudoir - Director of Marketing; Manasi Patwardhan - Director of Strategic Planning; Sasha Gentling, CFA - Director of Business Development and Investments
• Added as a member of the Russell 3000® Index
• Appointed Jerome Zeldis, M.D., Ph.D,, Samuel E. Navarro, and Martha Pease to Board of Directors
• Received $4.6 million in cash warrant and option exercises
• Announced that the US Patent & Trademark Office allowed 33 patent claims covering its PURE EP™ System
• Successfully conducted patient cases using PURE EP™ System at Indiana University School of Medicine, Texas Cardiac Arrhythmia Institute and Greenville Memorial Hospital

BioSig Technologies, Inc.

Contact:

Kenneth L. Londoner

Phone: [phone], x119 [e-mail]

Investor Relations

Phone: [phone] [e-mail]

Investment Catalysts

PURE EP™ System

Proven Team

Investment Highlights

Proprietary Hardware and Software with

BioSig is comprised of a stellar cast of a

• Member of the Russell 3000® Index

Advanced Signal Processing Capabilities:

proven

management

team

and

a

premier

•

Successfully Conducted First Patient Cases with

• To Improve Signal Clarity Through Reduction

Board of Directors with high levels of inside

PURE EP™

•

Management and

Insiders

Own Approx. 68%

of

of 'Noise' and Artifacts

equity ownership.

Shares

• To Minimize Need for Repeat Procedures

BioSig

brought

together leading

physicians,

• 10-year Strategic Collaboration with Mayo Clinic

• To Preserve Important Clinical Information

• Core competency in Basic Science, Capital Markets

executives

and

engineering

experts from

and Capital Architecture

• To Shorten Procedure Times

leading medical centers of excellence,

•

IP Strategy Led by Sherpa Technology Group and

• To

Increase Confidence

in Performing

healthcare programs, Fortune 500 Companies

Sterne Kessler Goldstein & Fox

Complex Ablations

and elite

educational institutions

including

• FDA clearance achieved; CE Mark-2020

• Proven Management Team and Board of Directors

Mayo

Clinic, Mount

Sinai Medical

Center,

• Global and Growing Addressable Market

UCLA,

Johnson

&

Johnson, Nasdaq

and

•

Operates Within

Rapidly

Emerging Field

of

Prudential Securities.

Bioelectronic Medicine

Kenneth L. Londoner, Chairman & CEO, has a

• High-GrowthSector Earns

Innovation Premium,

Aggressive M&A

wealth of knowledge and experience that

Collaborating with Leading EPs from:

spans many decades and includes founding,

Global

EP Market-10.6%

Growth from

running, and serving as Director to a number

of life science companies. Mr. Londoner began

2016-2024 reaching $8.5B by 2024

his career with J. & W. Seligman & Co., Inc., a

• Global Ablation: 865,000 patients in 2015 to

leading institutional money management firm

1,350,000 in 2020.

where

he

rose

from research

analyst

to

• Global Procedure Growth: 8.4% annual rate, managing $3.5 billion in mutual funds,

from 973,220 in 2017 to 1,455 million in	pension funds, and international assets. Steve
2022.		Chaussy, CFO has acted as a consultant for	Current Cardiac Arrhythmia Epidemic (1 in 18 or
• The FDA (www.fda.gov) presented at the Heart	small publicly	traded entities	with a special
14.4M Americans)
Rhythm Society 2017	and spoke of the	emphasis towards SEC reporting and
Two of the most prevalent and potentially deadly
compliance; and served as CFO for a large
importance of technological innovation in the
private distribution and wholesaling company,	types of arrhythmias today are Atrial Fibrillation
EP field.
	(AF) and Ventricular Tachycardia (VT). Ventricular
	where he gained international experience.
		arrhythmias account for approximately 450,000
		Their many accomplishments	and years of	sudden deaths per year in the United States
		alone. Catheter ablation is fast becoming a first
		experience of the management team, as well
		line therapy, driving demand for improved
		as the Board	of Directors	and Scientific
		technologies. AF is the most common arrhythmia
		Advisory Board, is unmatched and provides	affecting 33.5 million people worldwide, with as
		BioSig a clear advantage in the market.	many as 6.1 million people in the U.S. now and
					expected 8-12 million by 2050. AF increases the
					risk of stroke 4x to 5x and contributes to
					~750,000 hospitalizations per year. The direct
Management			Directors		cost of AF is approximately $6B annually; adding
			other indirect costs brings AF total cost to $26B.
Kenneth L. Londoner, MBA, Founder, Chairman, Chief
Donald E. Foley, Director - CEO & Chair: Wilmington Trust; Sr VP, Treas & Dir: ITT Corp; Asst
Executive Officer, Director
	Treas: International Paper Co.
Endicott Management Partners; J & W Seligman & Co; Director: Alliqua	David Weild IV, MBA, Director - Current Chairman & CEO; Weild & Co.; Vice Chairman:
Steve Chaussy, CPA, Chief Financial Officer
	NASDAQ; Head of Corporate Finance & Equity Markets: Prudential Securities
Liberski Inc; Anna & Co; Penske Truck Leasing, Ford, Hogg & Cobbe	Patrick J. Gallagher, MBA, Director - Mg Dir: Laidlaw & Co.; Kinex Pharmaceuticals;
Natasha Drapeau, Executive Vice President		Director: Cingulate Therapeutics, BDR Research Group, GC Capital Partners, Kidder Peabody
	Jeffrey F. O'Donnell, Sr., Director - Current CEO, Director: Trice Medical; Current Chair:
IG Group Plc, London, UK; Augeous Consulting, Geneva, Switzerland
SpectraWave; Director: AdvaMed Accel; Founder: Embrella Cardiovascular (sold to Edwards
Barry Keenan, Ph.D, MBA, PMP, VP, Engineering
Lifesciences); CEO: PhotoMedex, Radiance Medical (Cardiovascular Dynamics), Kensey Nash;
Medtronic, Nexeon MedSystems, Alfred Mann Institute for Biomedical	Sales/Mktg Mngt: Boston Scientific, Guidant, J&J; Former Director: Cardiac Science, Endologix
Engineering; Alfred Mann Foundation for Scientific Research	Andrew Filler, Director - Current Partner & General Counsel: Sherpa Technology Group,
John Kowalski, VP, Sales			Nanosys; IP Counsel: Previvo Genetics; Board: Aira Technologies. Former: Caliper Life Sciences
Biosense Webster (Johnson & Johnson)		(sold to Perkin Elmer), Weil, Gotshal & Manges
	Jerome Zeldis, M.D., Ph.D, Director - Chief Medical Officer and President of Clinical
Andrew Ballou, VP, Investor Relations
	Research, Medical Affairs Drug Safety, Quality, and Regulatory at Sorrento Therapeutics, Inc.
Janney Montgomery Scott LLC., RBC Capital Markets
	Samuel E. Navarro, Director - Managing Partner: Gravitas Healthcare, LLC; Former
Julie Stephenson, VP, Clinical Affairs
	Managing Director and Global Head of Medical Technology Investment Banking: Cowen &
Medtronic, Boston Scientific, Guidant Corporation		Company
Olivier Chaudoir, Sr. Director of Marketing		Martha Pease, Director - Current Partner and Director at BCG (Boston Consulting Group)
Biosense Webster, DePuy Synthes
Analyst Coverage	ROTH Capital Partners
Laidlaw & Co (UK) Ltd.	Chardan Capital Markets, LLC.

Disclaimer: This Corporate Summary Sheet includes forward-looking statements. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing, regulatory approvals, competition and marketplace demand. More information, and BioSig risk factors, are set forth in its filings with the SEC. BioSig assumes no obligation to publicly update or revise its forward-looking statements.